(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 16.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.99%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Rigel Pharmaceuticals's revenue in 2026 is $276,785,000.On average, 7 Wall Street analysts forecast RIGL's revenue for 2026 to be $5,877,245,610, with the lowest RIGL revenue forecast at $5,538,019,280, and the highest RIGL revenue forecast at $6,166,596,704. On average, 7 Wall Street analysts forecast RIGL's revenue for 2027 to be $7,087,513,999, with the lowest RIGL revenue forecast at $6,375,437,583, and the highest RIGL revenue forecast at $7,678,918,493.
In 2028, RIGL is forecast to generate $8,183,088,022 in revenue, with the lowest revenue forecast at $7,109,369,440 and the highest revenue forecast at $9,138,189,469.